Tyson 2.0 Enters the European Medical Cannabis Market

Tyson 2.0, a cannabis brand founded by the legendary boxer, entrepreneur, and legalization advocate Mike Tyson, is expanding its reach into the European market. This move is in collaboration with PHCANN International, a leading international pharmaceutical conglomerate, and Carma HoldCo Inc., promising a revolution in access to THC-based products such as dried flower, concentrates, and edibles in Germany and the United Kingdom. The announcement of this partnership was made just before the International Cannabis Business Conference (ICBC) in Berlin on April 16-17, which will feature various representatives.

“Partnering with PHCANN to introduce my top-quality Tyson 2.0 Indian hemp products in Germany and the UK is a natural move for industry leaders,” said Tyson 2.0 co-founder and brand director Mike Tyson. “I am excited about the opportunity to offer our world-class products to medical cannabis patients in the region. Together, we are setting new standards and offering something that no one else does.”

For more news like this, along with all the latest in legalization, research, and lifestyle, download our free cannabis news app.

History of the Tyson 2.0 Brand

Before entering the European market, the Tyson 2.0 brand was launched in 2021, with the mission of providing the highest quality cannabis-based products. Mike Tyson, not only as a co-founder but also as the chief ambassador, has transferred his unwavering pursuit to be the best from the boxing ring to the cannabis industry. His commitment has helped the brand quickly gain international recognition, expanding its operations to the United States and 16 other countries, continuously conquering more global markets.

Partnership With PHCANN International and Carma HoldCo

PHCANN International, headquartered in Amsterdam, is renowned for adhering to EU GMP standards and operates one of the largest cultivation facilities in Europe. The collaboration with Tyson 2.0 will allow for the cultivation and production of exclusive cannabis strains, set to hit the German and British markets this summer. Meanwhile, Carma HoldCo, known for creating powerful brands like Ric Flair Drip, has brought its experience in global branding and marketing. Adam Wilks, CEO of Carma, emphasized that the partnership with Tyson 2.0 is a key step in expanding the company’s global presence and delivering the highest quality products.

Implications for the European Market

The introduction of the Tyson 2.0 brand to Europe represents not only new opportunities for consumers but also a significant boost for the developing medical cannabis market. Germany and the United Kingdom are key markets in Europe with a growing demand for legal cannabis products. In the context of changing legal regulations in these countries, Tyson 2.0 could become a pioneer of new standards and raise the bar for the entire industry.

Expectations and Future Steps for Tyson 2.0

The ongoing ICBC conference in Berlin will be an ideal opportunity to showcase the Tyson 2.0 brand to European investors and business partners. It is also a chance to further strengthen the brand’s position on the global market. The company plans to continue its expansion by increasing the availability of its products and entering new markets, always keeping in mind the highest quality and innovation.

Summary

The expansion of Tyson 2.0 into European markets is more than just the introduction of new products—it is a herald of transformation for the entire industry. With Mike Tyson at the helm, the company not only delivers exceptional products but also changes perceptions and approaches to cannabis around the world. As Europe stands on the cusp of further legal regulations regarding cannabis, Tyson 2.0 could play a crucial role in shaping the future of this dynamically growing industry.

—

(Featured image courtesy of Tyson 2.0)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Fakty Konopne, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.